Articles

Found results: 16338

Biomedicine

Biopharmaceuticals: originals and analogues

Analogues of biopharmaceutical drugs are called biosimilars or bioengineers, in the USA they are called modified biopharmaceuticals. Reproduced biopharmaceuticals are also called "biosimilars" ("biosimilars"), and this term has been used most frequently in recent years.

18.06.2009
Controversial

Cyborgs are among us

While genetic engineers are looking for arguments in a dispute with the authorities about cloning, ordinary engineers have already begun to turn humanity into cyborgs.

17.06.2009
New in Gerontology

The key target of the aging regulator has been discovered

Sirtuins at the cellular level maintain the integrity of the genome, increase resistance to adverse factors and resist physiological aging. Scientists from the Wistar Institute for the first time demonstrated the molecular target of one of the representatives of this class of proteins, Sir2, in the process of regulating the aging of yeast cells.

17.06.2009
Note to the businessman

Russian Pharmaceutical Forum 2009: the strongest survives the crisis

Hundreds of participants, not only from different parts of Russia, but also from all over the world, came to the Adam Smith Institute conference "Russian Pharmaceutical Forum" to try to figure out for themselves how Russian pharma will develop in the era of the global economic crisis.

16.06.2009
Genetics

Genes of schizophrenia and depression: the answer is close

Comparison of isolated populations with frequent occurrence of the same disease makes it possible to determine the entire spectrum of genes associated with it. This approach allowed us to establish a number of important facts in the identification of schizophrenia and depression genes.

16.06.2009
New in Gerontology

The most complete database on life expectancy

Unlike many other resources of this kind, the AnAge database includes only scientifically confirmed data. The database contains information about the maximum life expectancy of 3,650 vertebrate species (humans are in 11th place among them), as well as body weight, growth and puberty rates, reproduction rate and other characteristics that can be used for comparative studies.

16.06.2009
Genetics

All the genes of all diseases in one database

The project of scientists from Olga Troyanskaya's group at Princeton University has become part of the revolution in medical and biological science that has been taking place in recent years. Data on the function of genes and their activity in various diseases are now collected in one place, and everyone can get acquainted with them.

16.06.2009
Biotechnologies - into life

The path of the innovator: Moscow – Harvard – Boston

He was the youngest professor at Moscow State University, winner of the Lenin Komsomol Prize and winner of the USSR State Prize. He now lives in Boston. Anatoly Klesov has passed the classic path of an innovator, about which a lot of textbooks are written. And now he is a shareholder of an enterprise that uses his developments in the field of composite materials and vice president of a biotech company developing anti-cancer drugs.

15.06.2009
Note to the businessman

Venture and seed funds of nanotechnology

RUSNANO plans to participate in 5 main types of venture funds: nanotechnology seed funds, low-budget project funds, industry funds, international nanotechnology funds, as well as funds organized under intergovernmental agreements.

15.06.2009
Nanotechnology

Gallop on nanotechnology

If you think that nanotechnology is a distant future or even the lot of science fiction, then you are mistaken. Nature "invented" nanotechnology (as well as many other things) long before man, who only in the last few decades has been following the same path, trying to repeat some of her inventions. The successes so far are quite modest, but scientists have already managed to achieve some achievements in the field of nanotechnology.

11.06.2009
Note to the businessman

Officials are against innovation

The Strategy for the development of the pharmaceutical industry of the Russian Federation until 2020 is based on two main theses: the creation of innovative drugs and the import substitution program. If every worthwhile innovative drug makes its way to the domestic market with such a fight, and the reasons for the verdict "not fit" will be hidden by officials, the strategy will not be implemented.

11.06.2009
Innovative Russia

Resuscitation of innovations

Participants of the international forum "Days of Russian Innovations" presented specific projects to stimulate innovation.

11.06.2009
Healthy skepticism

From the hands of A and F do not accept advertising

The leadership of the Federal State Institution "Russian Cardiology Center" addressed a letter to the editor-in-chief of the newspaper "AIF" N.I. Zyatkov, in which, in particular, it says: "thousands of patients can quit treatment and then, indeed, the epidemic of stroke will begin. Have you thought, Mr. Editor, what this advertisement can bring?"

10.06.2009
Grants and competitions

According to the Hamburg account

The purpose of the Program is to enable young specialists from St. Petersburg and the North–Western region of Russia to undergo training and specialization at enterprises and organizations in the city of Hamburg.

08.06.2009
Biomedicine

RNA interference: Silencing genes

Classical RNA interference is the action of siRNA, the other short RNAs (microRNAs and antigenrnas) resemble interference to some extent by the mechanism of action, but do not fit into the usual scheme.

04.06.2009